Regorafenib with or without chemotherapy/immunotherapy in second-line treatment of metastatic colorectal cancer during the COVID-19 pandemic: a single-center retrospective analysis.

27.0 months), although this difference did not reach statistical significance (P=0.17) ( Figure 2F ).

also in 111,027 other papers

Subgroup analysis revealed that patients with liver metastases at the initiation of regorafenib therapy showed a trend toward worse outcomes compared to those without liver metastases.

also in 53,322 other papers